<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804776</url>
  </required_header>
  <id_info>
    <org_study_id>ECRU-LUNG-2013</org_study_id>
    <nct_id>NCT02804776</nct_id>
  </id_info>
  <brief_title>PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for&#xD;
      patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selected patients will receive 4 weeks of gefitinib before surgery. A Positron Emission&#xD;
      Tomography - Computed Tomography (PET- CT) will be performed before and after gefitinib to&#xD;
      assess the response. Circulating tumour cells (CTCs) and plasma Deoxyribonucleic acid (DNA)&#xD;
      will be acquired at baseline, 2 weeks and 4 weeks after gefitinib treatment. Resected tumor&#xD;
      will be sectored in details to study the spatial heterogeneity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2015</start_date>
  <completion_date type="Actual">February 21, 2018</completion_date>
  <primary_completion_date type="Actual">February 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EGFR TKI sensitivity biomarkers determination</measure>
    <time_frame>4 to 6 weeks</time_frame>
    <description>Determine EGFR tyrosine kinase inhibitor (TKI) sensitivity biomarkers in responders vs non responders, as categorized by either Response Evaluation Criteria In Solid Tumors (RECIST) stable disease (SD) vs Partial response (PR) or median percentage tumour shrinkage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates after 4 weeks of neoadjuvant gefitinib</measure>
    <time_frame>4 to 6 weeks</time_frame>
    <description>To determine response rates after 4 weeks of neoadjuvant gefitinib as evaluated by RECIST 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clonal heterogeneity using whole exome and RNA-sequencing of tumour sectors as well as resected lymph nodes</measure>
    <time_frame>4 to 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clonal heterogeneity recapitulation through CTC, plasma DNA and functional imaging</measure>
    <time_frame>4 to 6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250mg oral daily for 4 weeks</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  EGFR mutation positive Non-Small Cell lung cancer (NSCLC) (regardless of smoking&#xD;
             status), or control group may encompass other molecular subtypes of lung cancer e.g.&#xD;
             anaplastic lymphoma kinase (ALK) and Kirsten rat sarcoma viral oncogene homolog&#xD;
             (KRAS).&#xD;
&#xD;
          -  All early stage patients with NSCLC who are deemed surgically resectable.&#xD;
&#xD;
          -  All patients must have histologically proven NSCLC, with known EGFR mutation&#xD;
&#xD;
          -  Patients should be fit for either lobectomy/ pneumonectomy with or without lymph node&#xD;
             sampling.&#xD;
&#xD;
          -  Primary tumour should be at least 2 cm in size (Tumor stage 1b).&#xD;
&#xD;
          -  Willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known severe hypersensitivity to gefitinib or any of the excipients of this product&#xD;
&#xD;
          -  Any serious concomitant systemic disorder that, in the opinion of the investigator,&#xD;
             would compromise the patient's ability to complete the study.&#xD;
&#xD;
          -  Interstitial lung disease (ILD) or pulmonary fibrosis; impaired pulmonary function&#xD;
             (e.g. FEV1 &lt;40% predicted value, artery blood gas PaO2&lt;60mmHg)&#xD;
&#xD;
          -  Patients with prior exposure to agents directed at the Human epidermal receptor (HER)&#xD;
             axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).&#xD;
&#xD;
          -  Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer&#xD;
             therapy (e.g. monoclonal antibody therapy) for lung cancer.&#xD;
&#xD;
          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, myocardial infarction within six months,&#xD;
             serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic&#xD;
             disease).&#xD;
&#xD;
          -  Evidence of any other disease, neurological or metabolic dysfunction, physical&#xD;
             examination or laboratory finding giving reasonable suspicion of a disease or&#xD;
             condition that contraindicates the use of an investigational drug or puts the subject&#xD;
             at high risk for treatment-related complications.&#xD;
&#xD;
          -  Patient who has serious active infection.&#xD;
&#xD;
          -  Patients who harbouring exon 20 T(Threonine)790M (Methionine) mutation.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel SW Tan</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

